Dexmedetomidine for Refractory Intracranial Hypertension

Kendra J. Schomer, Christian Sebat, Jason Y. Adams, Jeremiah J. Duby, Kiarash Shahlaie, Erin L. Louie

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Dexmedetomidine (DEX) is a selective α2 adrenergic agonist that is commonly used for sedation in the intensive care unit (ICU). The role of DEX for adjunctive treatment of refractory intracranial hypertension is poorly defined. The primary objective of this study was to determine the effect of DEX on the need for rescue therapy (ie, hyperosmolar boluses, extraventricular drain [EVD] drainages) for refractory intracranial hypertension. Secondary objectives included the number of intracranial pressure (ICP) excursions, bradycardic, hypotensive, and compromised cerebral perfusion pressure episodes. This retrospective cohort study evaluated patients admitted to the neurosurgical ICU from August 1, 2009, to July 29, 2015, and who received DEX for refractory intracranial hypertension. The objectives were compared between the 2 time periods—before (pre-DEX) and during therapy (DEX). Twenty-three patients with 26 episodes of refractory intracranial hypertension met the inclusion criteria. The number of hyperosmolar boluses was decreased after DEX therapy was initiated. Mannitol boluses required were statistically reduced (1 vs 0.5, P =.03); however, reduction in hypertonic boluses was not statistically significant (1.3 vs 0.9, P =.2). The mean number of EVD drainages per 24 hours was not significantly different between the time periods (15.7 vs 14.0, P =.35). The rate of ICP excursions did not differ between the 2 groups (24.3 vs 22.5, P =.62). When compared to pre-DEX data, there was no difference in the median number of hypotensive (0 vs 0), bradycardic (0 vs 0), or compromised cerebral perfusion pressure episodes (0.5 vs 1.0). Dexmedetomidine may avoid increases in the need for rescue therapy when used as an adjunctive treatment of refractory intracranial hypertension without compromising hemodynamics.

Original languageEnglish (US)
Pages (from-to)62-66
Number of pages5
JournalJournal of Intensive Care Medicine
Volume34
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Dexmedetomidine
Intracranial Hypertension
Cerebrovascular Circulation
Intracranial Pressure
Intensive Care Units
Drainage
Therapeutics
Adrenergic Agonists
Mannitol
Cohort Studies
Retrospective Studies
Hemodynamics

Keywords

  • adult brain injury
  • clinical management of CNS injury
  • head trauma
  • intracranial pressure
  • traumatic brain injury

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Dexmedetomidine for Refractory Intracranial Hypertension. / Schomer, Kendra J.; Sebat, Christian; Adams, Jason Y.; Duby, Jeremiah J.; Shahlaie, Kiarash; Louie, Erin L.

In: Journal of Intensive Care Medicine, Vol. 34, No. 1, 01.01.2019, p. 62-66.

Research output: Contribution to journalArticle

Schomer, Kendra J. ; Sebat, Christian ; Adams, Jason Y. ; Duby, Jeremiah J. ; Shahlaie, Kiarash ; Louie, Erin L. / Dexmedetomidine for Refractory Intracranial Hypertension. In: Journal of Intensive Care Medicine. 2019 ; Vol. 34, No. 1. pp. 62-66.
@article{bf858929a9544455a1522b48b877c080,
title = "Dexmedetomidine for Refractory Intracranial Hypertension",
abstract = "Dexmedetomidine (DEX) is a selective α2 adrenergic agonist that is commonly used for sedation in the intensive care unit (ICU). The role of DEX for adjunctive treatment of refractory intracranial hypertension is poorly defined. The primary objective of this study was to determine the effect of DEX on the need for rescue therapy (ie, hyperosmolar boluses, extraventricular drain [EVD] drainages) for refractory intracranial hypertension. Secondary objectives included the number of intracranial pressure (ICP) excursions, bradycardic, hypotensive, and compromised cerebral perfusion pressure episodes. This retrospective cohort study evaluated patients admitted to the neurosurgical ICU from August 1, 2009, to July 29, 2015, and who received DEX for refractory intracranial hypertension. The objectives were compared between the 2 time periods—before (pre-DEX) and during therapy (DEX). Twenty-three patients with 26 episodes of refractory intracranial hypertension met the inclusion criteria. The number of hyperosmolar boluses was decreased after DEX therapy was initiated. Mannitol boluses required were statistically reduced (1 vs 0.5, P =.03); however, reduction in hypertonic boluses was not statistically significant (1.3 vs 0.9, P =.2). The mean number of EVD drainages per 24 hours was not significantly different between the time periods (15.7 vs 14.0, P =.35). The rate of ICP excursions did not differ between the 2 groups (24.3 vs 22.5, P =.62). When compared to pre-DEX data, there was no difference in the median number of hypotensive (0 vs 0), bradycardic (0 vs 0), or compromised cerebral perfusion pressure episodes (0.5 vs 1.0). Dexmedetomidine may avoid increases in the need for rescue therapy when used as an adjunctive treatment of refractory intracranial hypertension without compromising hemodynamics.",
keywords = "adult brain injury, clinical management of CNS injury, head trauma, intracranial pressure, traumatic brain injury",
author = "Schomer, {Kendra J.} and Christian Sebat and Adams, {Jason Y.} and Duby, {Jeremiah J.} and Kiarash Shahlaie and Louie, {Erin L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/0885066616689555",
language = "English (US)",
volume = "34",
pages = "62--66",
journal = "Journal of Intensive Care Medicine",
issn = "0885-0666",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Dexmedetomidine for Refractory Intracranial Hypertension

AU - Schomer, Kendra J.

AU - Sebat, Christian

AU - Adams, Jason Y.

AU - Duby, Jeremiah J.

AU - Shahlaie, Kiarash

AU - Louie, Erin L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Dexmedetomidine (DEX) is a selective α2 adrenergic agonist that is commonly used for sedation in the intensive care unit (ICU). The role of DEX for adjunctive treatment of refractory intracranial hypertension is poorly defined. The primary objective of this study was to determine the effect of DEX on the need for rescue therapy (ie, hyperosmolar boluses, extraventricular drain [EVD] drainages) for refractory intracranial hypertension. Secondary objectives included the number of intracranial pressure (ICP) excursions, bradycardic, hypotensive, and compromised cerebral perfusion pressure episodes. This retrospective cohort study evaluated patients admitted to the neurosurgical ICU from August 1, 2009, to July 29, 2015, and who received DEX for refractory intracranial hypertension. The objectives were compared between the 2 time periods—before (pre-DEX) and during therapy (DEX). Twenty-three patients with 26 episodes of refractory intracranial hypertension met the inclusion criteria. The number of hyperosmolar boluses was decreased after DEX therapy was initiated. Mannitol boluses required were statistically reduced (1 vs 0.5, P =.03); however, reduction in hypertonic boluses was not statistically significant (1.3 vs 0.9, P =.2). The mean number of EVD drainages per 24 hours was not significantly different between the time periods (15.7 vs 14.0, P =.35). The rate of ICP excursions did not differ between the 2 groups (24.3 vs 22.5, P =.62). When compared to pre-DEX data, there was no difference in the median number of hypotensive (0 vs 0), bradycardic (0 vs 0), or compromised cerebral perfusion pressure episodes (0.5 vs 1.0). Dexmedetomidine may avoid increases in the need for rescue therapy when used as an adjunctive treatment of refractory intracranial hypertension without compromising hemodynamics.

AB - Dexmedetomidine (DEX) is a selective α2 adrenergic agonist that is commonly used for sedation in the intensive care unit (ICU). The role of DEX for adjunctive treatment of refractory intracranial hypertension is poorly defined. The primary objective of this study was to determine the effect of DEX on the need for rescue therapy (ie, hyperosmolar boluses, extraventricular drain [EVD] drainages) for refractory intracranial hypertension. Secondary objectives included the number of intracranial pressure (ICP) excursions, bradycardic, hypotensive, and compromised cerebral perfusion pressure episodes. This retrospective cohort study evaluated patients admitted to the neurosurgical ICU from August 1, 2009, to July 29, 2015, and who received DEX for refractory intracranial hypertension. The objectives were compared between the 2 time periods—before (pre-DEX) and during therapy (DEX). Twenty-three patients with 26 episodes of refractory intracranial hypertension met the inclusion criteria. The number of hyperosmolar boluses was decreased after DEX therapy was initiated. Mannitol boluses required were statistically reduced (1 vs 0.5, P =.03); however, reduction in hypertonic boluses was not statistically significant (1.3 vs 0.9, P =.2). The mean number of EVD drainages per 24 hours was not significantly different between the time periods (15.7 vs 14.0, P =.35). The rate of ICP excursions did not differ between the 2 groups (24.3 vs 22.5, P =.62). When compared to pre-DEX data, there was no difference in the median number of hypotensive (0 vs 0), bradycardic (0 vs 0), or compromised cerebral perfusion pressure episodes (0.5 vs 1.0). Dexmedetomidine may avoid increases in the need for rescue therapy when used as an adjunctive treatment of refractory intracranial hypertension without compromising hemodynamics.

KW - adult brain injury

KW - clinical management of CNS injury

KW - head trauma

KW - intracranial pressure

KW - traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85058108076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058108076&partnerID=8YFLogxK

U2 - 10.1177/0885066616689555

DO - 10.1177/0885066616689555

M3 - Article

VL - 34

SP - 62

EP - 66

JO - Journal of Intensive Care Medicine

JF - Journal of Intensive Care Medicine

SN - 0885-0666

IS - 1

ER -